Malignant brain tumor
Conditions
Interventions
Sponsors
Kondo Akihide
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Diagnosed with malignant brain tumor. (2)Patients scheduled to receive surgical resection, radiotherapy and chemotherapy as standard treatment. (3)70 or over of Karnofsky Performance Status (KPS) or Lansky Performance Status (LPS) score. (4)Life expectancy more than 2 months after initiation of the study therapy. (5)Age ranging over 3 years old and under 15 years old. (6)Possible to visit outpatient department. (7)Adequate function of liver, kidney, and bone marrow when eligibility is confirmed. (8)Written informed consent of guardian to participate this study.
Exclusion criteria
Exclusion criteria: (1)Apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia. (2)A history of a serious drug allergy. (3)Positive result of HIV or HTLV-1 antibody test. (4)A serious cardiac disorder. (5)Active autoimmune disorder. (6)Cancers other than malignant brain tumor. (7)An infectious disorder that is difficult to control.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy, Immunological response, Quality of therapeutic cells, Quality of life | — |
Countries
Japan
Contacts
Public ContactTakashi Kamigaki
Juntendo University
Outcome results
None listed